AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021

AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021

April 21, 2021 | Last Trade: US$4.39 0.09 2.09

AbCellera (Nasdaq: ABCL) will announce its first-quarter 2021 financial results on Thursday, May 13, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live webcast will be available on AbCellera’s Investor Relations website at: https://investors.abcellera.com/. Replay of the webcast will be available through the same link following the conference call.

About AbCellera

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. To learn more, please visit www.abcellera.com.

Source: AbCellera Biologics Inc.

Stock Quote

Last Trade:	US$4.39
Daily Change:	0.09 2.09
Daily Volume:	4,027,453
Market Cap:	US$1.310B

August 07, 2025 AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms May 30, 2025 AbCellera Biologics Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 May 14, 2025 AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause May 12, 2025 AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit May 09, 2025 AbCellera Biologics Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting LOAD MORE NEWS

Featured Stock

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE